Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reproxalap DED Chamber Trial
NCT06389214Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of reproxalap in dry eye disease (DED), sponsored by Aldeyra Therapeutics. Started Apr 2024; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06389214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389214.